阿托伐他汀对ACS患者介入治疗后hs-CRP、slCAM-1及sVCAM-1的影响  

Influence of atorvastatin on sICAM-1,sVCAM-1 and hs-CRP in acute coronary syndrome patients receiving percutaneous coronary intervention

作　　者：程小兵[1,2] 潘文博[1,2] 钟万生 杨玉雯[3,4] 徐承华[5,6] 周胜军 

机构地区：[1]合肥市第三人民医院心内科 [2]安徽医科大学合肥第三临床学院,合肥230022 [3]皖南医学院弋矶山医院心内科 [4]皖南医学院心血管研究所 [5]安徽中医药高等专科学校附属医院 [6]芜湖市中医院 [7]河北省秦皇岛市中心医院

出　　处：《临床心血管病杂志》2014年第5期402-404,共3页Journal of Clinical Cardiology

摘　　要：目的:观察不同剂量的阿托伐他汀对急性冠状动脉综合征(ACS)患者冠状动脉介入(PCI)围手术期的炎性因子及血清黏附因子的影响。方法:将入选的120例ACS患者,随机分为治疗组和对照组,每组60例,治疗组给予阿托伐他汀40mg/d,对照组给予阿托伐他汀20mg/d。于PCI术前、术后1周及2周测血浆高敏C反应蛋白(hs-CRP)、血浆可溶性细胞间黏附分子(sICAM-1)及血管细胞黏附分子(sVCAM-1)。结果:治疗组在PCI术后1周和2周,hs-CRP、sICAM-1和sVCAM-1显著低于对照组(P<0.01)。结论:较大剂量阿托伐他汀能够抑制PCI术后炎症反应,显著降低slCAM-1和sVCAM-1水平。Objective：To explore the influence of different doses of atorvastatin on adhesion molecule and inflammatory cytokines levels in acute coronary syndrome（ACS）patients receiving pereutaneons coronary intervention（PCI）.Method：The 120ACS patients were randomly divided into treatment group and control group,60cases in each group.The treatment group received atorvastatin 40mg/d,and the control group received atorvastatin 20 mg/d.We measured plasma hs-CRP,soluble intercellular adhesionmolecuh-1（sICAM-1）,and soluble vascular cell adhesion molecule-1（sVCAM-1）before PCI and after PCI in one and two weeks.Result：Compared with control group,hs-CRP,sICAM-1and sVCAM-1were decreased significantly in treatment group（P〈0.01）.Conclusion： Larger dose atorvastatin can inhibit inflammation after PCI and significantly reduced slCAM-1and sVCAM-1level.

关 键 词：急性冠状动脉综合征 阿托伐他汀 强化治疗 炎症因子 

分 类 号：R541.4[医药卫生—心血管疾病]